Key finding
Implant planning involves more than choosing a volume. Research on measurement systems, patient preferences and 3D simulation shows why dimensions can inform a consultation, while individual anatomy, uncertainty and long-term device decisions still matter.
Choosing a breast implant is not simply a matter of selecting a volume in cubic centimetres or naming a cup size. Width, projection and the surrounding tissue envelope help describe how an implant may relate to a person’s breast and chest. Measurements and images can make options easier to discuss, but neither a formula nor a simulation can identify a universally correct implant or promise a particular appearance.
Procedure scope and implant options are also part of comparing commercial estimates; see the breast augmentation cost in Turkey page for price information.
This evidence review concerns primary cosmetic breast augmentation. Results from reconstructive surgery, revision operations or different patient groups should not be assumed to apply to it. The studies below also ask different questions: one reviews how implant-selection systems were studied; another examines size satisfaction after surgery; and two evaluate 3D planning in separate settings.
Why volume is only one part of the plan
An implant’s labelled volume does not describe its full geometry. Two implants with the same volume can have different base widths and projections, and the same dimensions can sit differently on different chests. The soft-tissue envelope, existing breast shape, skin and tissue characteristics, asymmetry, chest-wall form and a person’s preferences all contribute to the planning conversation. A cup-size label is not a measurement of the implant itself and cannot reliably specify the result.
A systematic review by Adams and McKee identified 33 published implant size-selection systems for primary augmentation. Only four of the 33 papers (12%) reported clinical outcomes that could be compared with accepted literature values or industry standards. The review rated tissue-based planning systems, which use clinical guidelines to select patient-specific implant dimensions, as methodologically stronger on the MINORS scale than systems centred on dimensional analyses shaped by patient or surgeon preference, or systems that did not measure the breast: mean scores were 6.0 ± 1.4, 1.4 ± 2.3 and 0.0 ± 0.0, respectively. The authors found some evidence supporting tissue-based planning and reported that studies using it had lower reoperation rates than cited benchmarks. This is comparative evidence from a review of a limited and methodologically uneven literature; it does not prove that one named system is best for every patient or that measurements alone prevent reoperation.
Measurements organise discussion; they do not settle it
Measurements can help a surgeon compare an implant’s base width with breast and chest dimensions, consider projection, and discuss the available range of shapes. They are inputs to clinical judgement rather than a stand-alone prescription. Even the measurement method matters: landmarks, posture, tissue compression and the person taking the measurement can affect the recorded value.
In a 2024 single-practice retrospective study, Akgun Demir assessed 69 women having primary augmentation between May 2022 and December 2023. The study analysed 138 breast-width measurements: clinical caliper assessment (CA), Vectra XT 3D measurements using automatic landmarks (VA), and 3D measurements after landmarks were marked on the patient and manually positioned (VM). The inframammary fold had to be visible or the lower breast border unobscured in the 3D image. The study compared each method’s suggested implant base width with the width of the implant actually used.
| Measure | Mean suggested width (cm) | Mean difference from actual implant width | Agreement with actual width (ICC) |
|---|---|---|---|
| Actual implant | 11.01 ± 0.67 | Reference | — |
| Clinical assessment (CA) | 10.75 ± 1.02 | −2.4% ± 5.9% | 0.834 |
| Automatic 3D landmarks (VA) | 12.05 ± 1.27 | +9.5% ± 10.1% | 0.568 |
| Manually positioned 3D landmarks (VM) | 11.81 ± 1.13 | +7.2% ± 6.7% | 0.793 |
Values are mean ± standard deviation (SD); percentage differences are the mean relative difference ± SD. ICC is the intraclass correlation coefficient. The source table does not identify the interval type for the parenthetical ICC ranges, so those ranges are omitted here.
All three methods correlated positively with the implant width used. Clinical measurements had the highest intraclass correlation coefficient (ICC), followed by manually positioned and then automatic 3D measurements. The average difference for CA was −2.4%, compared with +9.5% for VA and +7.2% for VM; manual positioning reduced the rate of change relative to automatic landmarking (P < .05). The ranges were wide, however: for example, automatic measurements ranged from 30.2% below to 35.7% above the actual width. An ICC describes agreement in this study; it is not a measure of satisfaction, safety or aesthetic success.
These numbers are not a contest in which the method nearest the cohort average should determine an individual’s implant. The study used one surgeon’s practice, had no random allocation, and included a selected group with visible anatomical landmarks. The operator proposed the manual-marking method and performed the assessments; results may differ with other clinicians, devices, populations or surgical approaches. Follow-up averaged 9.7 months (range 2–20), but the central comparison was measurement agreement, not long-term patient-reported outcomes. It cannot establish that one method creates a better-looking result or fewer complications.
Patient preference is an outcome to discuss, not a number to calculate
Planning should make room for what a person hopes to change and how they describe a satisfactory result. A volume or measurement cannot substitute for that conversation, and a patient’s preference does not by itself determine what is clinically suitable.
Brown’s observational study followed 341 patients who underwent subfascial augmentation in one practice. At three months, a survey asked whether the patient wanted a smaller implant, a larger implant or no change in size. Of the 341 respondents, 259 (76.0%) wanted no change, 57 (16.7%) wanted a larger implant and 25 (7.3%) wanted a smaller one. The author calculated an empirical ratio from breast width, implant width and projection (Rib). Mean Rib values were 5.8 ± 0.9 in the no-change group, 5.6 ± 1.1 among those wanting larger implants and 5.3 ± 1.3 among those wanting smaller implants; the overall group difference was reported as H(341) = 14.0, P < .01.
The survey was taken at three months, a particular point in recovery, and recorded a preference about size rather than a complete assessment of satisfaction or long-term outcome. The ratio was developed empirically in this cohort. The author explicitly cautioned that it should not be relied on for everyday clinical decisions; it may help standardise future research. It is therefore not a validated calculator, a target value or evidence that matching a ratio will cause satisfaction.
Three-dimensional simulation has limits
A 3D image may help people and clinicians talk through shape, asymmetry and possible changes from different viewpoints. A simulated image remains a visual aid based on assumptions and captured measurements; it is not a photograph of a guaranteed future result. Landmark placement, posture, tissue characteristics and the software’s model can affect what appears on screen.
Overschmidt and colleagues prospectively enrolled 100 patients in a study of primary augmentation with randomised and non-randomised groups. The randomised comparison was small: 13 patients received tissue-based planning without simulation and 10 were simulated. The remaining patients had sought simulation and were not randomised. BREAST-Q patient-reported outcomes and breast measurements were collected before surgery and at six months. More participants declined randomisation and chose simulation over time (P = .03). Although augmentation was associated with improvements in breast satisfaction, sexual well-being and outcome ratings, simulation did not significantly change patient-reported outcomes or mammometric measures. The authors concluded that patients may value simulation if they believe it helps them understand a possible result, but its addition did not produce clinically meaningful changes in the outcomes measured.
Because only 23 participants were in the randomised arms and preference influenced entry into the non-randomised group, this study cannot rule out every possible benefit or establish effects for all settings. It also does not test every simulation system. A separate 2024 retrospective study of Vectra XT measurements (described above) found that manually placing landmarks improved agreement compared with automatic landmarking, but still did not establish that simulation predicts an individual’s final appearance. Together, these studies support treating 3D imaging as an aid to communication and measurement, not a guarantee or replacement for examination and clinical planning.
Questions that make a planning conversation clearer
A useful consultation connects a person’s goals with anatomy, options, uncertainty and future care. Consider asking the treating clinician:
- Which measurements of my breast and chest are shaping the proposed implant width, projection and position?
- How do my existing asymmetry, tissue thickness and skin characteristics affect the options?
- If 3D imaging is used, what does it represent, how are landmarks placed, and which details cannot be predicted from it?
- What are the trade-offs between the options discussed, including the possibility that the result may differ from a simulation?
- What implant-specific risks, follow-up and future imaging or replacement decisions should I understand?
- What alternatives, including no implant, are relevant to my circumstances and preferences?
Device information and future decisions
Implant choice also involves understanding the device and its longer-term implications. The US Food and Drug Administration (FDA) issued non-binding labelling guidance recommending a patient decision checklist to support discussion of benefits and risks. It notes that implants are not lifetime devices and that the likelihood of complications and further operations increases over time. Its checklist states that as many as 20% of women who receive implants for augmentation may have them removed within 8 to 10 years; an individual’s experience may be shorter or longer. That figure is a broad US patient-information statement, not a personalised prediction or a result of the implant-planning studies summarised here.
The FDA guidance also discusses implant rupture, the possibility that silicone-gel rupture may not be apparent on examination, and periodic imaging recommendations for silicone-gel implants in the United States. Recommendations and regulatory status vary by country and can change; people should ask their treating clinician which device information and follow-up guidance apply where their care takes place. This article is educational research content, not individual medical advice. When comparing how commercial packages describe their arrangements, see the breast augmentation package page and confirm follow-up arrangements directly with the treating clinician. Just Clinic Istanbul is an independent marketing and lead-generation platform, not a healthcare provider or medical tourism intermediary. Enquiries may be shared with authorised healthcare partners with consent.
References
- Adams WP Jr, McKee D. Matching the Implant to the Breast: A Systematic Review of Implant Size Selection Systems for Breast Augmentation. Plastic and Reconstructive Surgery. 2016 Nov;138(5):987–994. Published in the November 2016 issue. doi: 10.1097/PRS.0000000000002623. PMID: 27782989. Abstract accessed; full text not verified as accessible.
- Brown T. Observations Concerning the Match between Breast Implant Dimensions, Breast Morphometry, and a Patient-reported Outcome. Plastic and Reconstructive Surgery Global Open. Published online 25 January 2021; 2021 Jan;9(1):e3370. doi: 10.1097/GOX.0000000000003370. PMID: 33552817. Open-access full text.
- Overschmidt B, Qureshi AA, Parikh RP, Yan Y, Tenenbaum MM, Myckatyn TP. A Prospective Evaluation of Three-Dimensional Image Simulation: Patient-Reported Outcomes and Mammometrics in Primary Breast Augmentation. Plastic and Reconstructive Surgery. 2018 Aug;142(2):133e–144e. doi: 10.1097/PRS.0000000000004601. PMID: 30045174. Abstract accessed; full text not verified as accessible.
- Akgun Demir I. Optimizing Implant Width Selection in Breast Augmentation: Insights From On-Patient Landmark Positioning in 3-Dimensional Breast Simulation. Aesthetic Surgery Journal. Published online 20 February 2024; 2024 Sep;44(9):909–914. doi: 10.1093/asj/sjae040. PMID: 38377409. Full text accessed.
- U.S. Food and Drug Administration. Breast Implants — Certain Labeling Recommendations to Improve Patient Communication: Guidance for Industry and Food and Drug Administration Staff. Published 29 September 2020. Full guidance: FDA PDF. Non-binding US guidance, not a clinical study.